Molecular docking of 1,3,4-oxadiazoles: a step toward novel tuberculosis therapies
DOI:
https://doi.org/10.60988/p.v37i2S.146Keywords:
tuberculosis; antitubercular agents; protein-tyrosine-phosphatase; 1,3,4-oxadiazole; molecular dockingAbstract
Tuberculosis remains a major global health challenge, especially with the rise of multidrug-resistant strains that demand new treatment strategies. One promising target is the Mycobacterium protein-tyrosine-phosphatase B (MptpB), which helps Mycobacterium tuberculosis evade the immune system. This study explores the potential of 1,3,4-oxadiazole derivatives as inhibitors of MptpB. Using advanced molecular docking techniques, four derivatives of 5-(thiophen-2-yl)-1,3,4-oxadiazole-2-amine were designed and evaluated. These compounds were assessed for their ability to bind to the active site of MptpB. Among them, two showed significant potential, with compound #1 achieving a docking score of -8.8 kcal/mol; the highest in the study. Detailed interactions, including multiple hydrogen bonds and hydrophobic contacts, suggest strong binding affinity and stability within the active site. The findings highlight these compounds as promising candidates for new tuberculosis treatments, addressing the urgent need for innovative approaches to combat resistant strains. Further experimental validation and biological studies are necessary in order to translate these computational insights into practical therapeutic applications.
References
Comas I., Coscolla M., Luo T., Borrell S., Holt K.E., Kato-Maeda M., et al. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat. Genet. 45(10), 1176–1182, 2013. DOI: 10.1038/ng.2744
Chandra P., Grigsby S.J., Philips J.A. Immune evasion and provocation by Mycobacterium tuberculosis. Nat. Rev. Microbiol. 20(12), 750–766, 2022. DOI: 10.1038/s41579-022-00763-4
Ruddraraju K.V., Zhang Z.Y. Covalent inhibition of protein tyrosine phosphatases. Mol. Biosyst. 13(7), 1257–1279, 2017. DOI: 10.1039/c7mb00151g
Ribet D., Cossart P. How bacterial pathogens colonize their hosts and invade deeper tissues. Microbes Infect. 17(3), 173–183, 2015. DOI: 10.1016/j.micinf.2015.01.004
Bright N.A., Gratian M.J., Luzio J.P. Endocytic delivery to lysosomes mediated by concurrent fusion and kissing events in living cells. Curr. Biol. 15(4), 360–365, 2005. DOI: 10.1016/j.cub.2005.01.049
Kapila I., Bharwal A., Sharma P., Choudhary N., Abbot V. Synthetic marvels in tuberculosis research: an in-depth review of 1,3,4-oxadiazole derivatives as antitubercular agents. Eur. J. Med. Chem. Rep. 11, 100150, 2024. DOI: 10.1016/j.ejmcr.2024.100150
Verma S.K., Verma R., Verma S., Vaishnav Y., Tiwari S.P., Rakesh K.P. Anti-tuberculosis activity and its structure-activity relationship (SAR) studies of oxadiazole derivatives: a key review. Eur. J. Med. Chem. 209, 112886, 2021. DOI: 10.1016/j.ejmech.2020.112886
Grundner C., Perrin D., Hooft van Huijsduijnen R., Swinnen D., Gonzalez J., Gee C.L., et al. Structural basis for selective inhibition of Mycobacterium tuberculosis protein tyrosine phosphatase PtpB. Structure 15(4), 499–509, 2007. DOI: 10.1016/j.str.2007.03.003
Ali Y.S., Mahdi M.F., Abd Razik B.M. In silico evaluation of binding interaction and ADME properties of novel 5-(thiophen-2-yl)-1,3,4-oxadiazole-2-amine derivatives as anti-proliferative agents. Int. J. Appl. Pharm. 15(1), 141–146, 2023. DOI: 10.22159/ijap.2023v15i1.46488
